Zevra Q4 2021 Earnings Report
Key Takeaways
KemPharm reported Q4 2021 revenue of $2.6 million and a net loss of ($2.7) million. The company's cash, cash equivalents, and long-term investments totaled $127.8 million as of December 31, 2021.
KemPharm advanced on multiple fronts during the fourth quarter of 2021 and into early 2022, focusing on rare CNS and neurodegenerative conditions.
Strategic focus on developing and commercializing therapeutics targeting rare CNS and neurodegenerative conditions starting with KP1077.
Data from Phase 1 clinical trial validates selection of KP1077 as lead product candidate.
Company expects to file IND application for KP1077 as early as the second quarter of 2022 and initiate a Phase 2 clinical trial later in the year.
Zevra
Zevra
Forward Guidance
KemPharm's existing cash, cash equivalents and long-term investments are expected to be sufficient to continue operations through and beyond 2025.